Supplement Figure 1: RNA-seq analysis of Myc-CaP primary and metastatic tumors. (A) Gene Ontology (GO) enrichment analysis was performed with DAVID. (B) Heat maps of DAVID GO categories from (A). Supplement Figure 2: PCa cell line response in vitro to inhibition of TOP2 and EZH2. (A) murine Myc-CaP and (B) human LnCaP PCa cell lines were treated with the EZH2 inhibitor; GSK126 (GSK) or the TOP2 inhibitor; Etoposide (ETP) as indicated. Cell death was assessed by uptake of propidium iodide (PI), quantitated by flow cytometry. (C) Cell cycle analysis of Myc-CaP, LnCaP and TRAMP-C2 cell lines respectively. Cells were treated as indicated for 48h then fixed in 50°/o ethanol/PBS overnight. Cells were stained with PI and analyzed by flow cytometry. Supplement Figure 3: Combination inhibition of TOP2 and EZH2 increase therapeutic efficacy in vivo. (A) Weekly body weights of tumor bearing animals indicates no toxicity was induced within treatment groups. (B) Individual tumor measurements from figure 4A. (C) Example micrographs of FFPE Myc-CaP tumor samples stained with Hematoxylin and Eosin (H&E). Magnification x40. Supplement Figure 4: Combination inhibition of TOP2 and EZH2 increase therapeutic efficacy in vivo. (A} Weekly body weights of tumor bearing animals indicates no toxicity was induced within treatment groups. (B) Endpoint TRAMP-C2 tumor weights (DZ vs. COMBO *p=0.01; ETP vs. COMBO *p=0.02). (C) Individual TRAMP-C2 tumor measurements from figure 4C. (C) Example micrographs of FFPE TRAMP-C2 tumors stained with H&E; Immunohistochemistry (IHC) for H3K27me3, Ki67. Magnification x40.
